With a $207,000 grant co-funded by Bristol-Myers Squibb and Pfizer, a collaboration of clinical and health outcomes researchers at UH College of Pharmacy is launching a retrospective study on the efficacy and safety of anticoagulant therapy in conjunction with antiarrhythmic therapy in patients with non-valvular atrial fibrillation (NVAF).